On World ALS Day in June 2026, Cai Lei, the former JD.com executive turned prominent activist, faced a bittersweet milestone. Having lived with Amyotrophic Lateral Sclerosis (ALS) for seven years, Cai has transitioned from a high-flying tech leader to a 'frozen' patient whose body is failing him, even as his mind remains focused on a singular mission: making life-saving technology affordable for China’s rare disease community.
In late 2025, Cai partnered with Haier Smart Home to develop a customized, non-invasive ventilator specifically for ALS patients. Using a Consumer-to-Manufacturer (C2M) model, Haier managed to strip away unnecessary costs, producing a device priced 80% lower than dominant Swedish or Australian imports. However, despite the potential to save lives in a community where many earn less than 3,000 RMB ($415) per month, the response has been surprisingly tepid.
Of an initial projected demand for 1,000 units, only 500 were pre-ordered. The venture has met with unexpected resistance, fueled by a mixture of deep-seated brand prejudice and a predatory secondary market. In China, imported medical hardware—such as those from ResMed or Breas—has long been viewed as the gold standard for reliability. For ALS patients, where a machine failure or poor calibration can lead to immediate respiratory arrest, 'cheap' is often synonymous with 'risky.'
Compounding this skepticism is the interference of middlemen and second-hand dealers. As the Haier project launched, some distributors of expensive foreign brands began spreading disinformation in patient groups, suggesting that the lower price point indicated inferior safety. This friction highlights a painful reality in China’s healthcare landscape: for the most vulnerable, trust is often more expensive than the hardware itself.
Yet, the technical challenges are genuine. Unlike standard sleep apnea machines, ALS ventilators must operate 24/7 and require precise, adaptive algorithms to compensate for deteriorating muscle function. Haier’s team found that moving from hospital-grade equipment to home-based care requires an intensive service layer—engineers must constantly adjust parameters remotely as a patient’s condition evolves, a service cost that foreign brands often bake into their premium pricing.
Cai Lei views this lukewarm reception not as a failure, but as a necessary catalyst for a domestic medical ecosystem. He argues that rare disease markets are naturally unattractive to traditional capital due to their small scale, making it essential for patients to organize and pull manufacturers into the space. Without such collaboration, Chinese patients remain trapped between the 'unaffordable' new machines and 'unreliable' second-hand units circulating in chat groups.
Looking ahead, the Cai-Haier partnership aims to expand beyond breathing support to include cough-assist machines, smart nursing beds, and eye-tracking interfaces. The goal is to move the needle from passive 'rescue' to active innovation. For Cai, the struggle is no longer just about his own survival, but about proving that Chinese manufacturing can provide a high-tech safety net for those the market has historically ignored.